Amalgamated Financial’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Amalgamated Financial’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$461K	Buy	+3,634	New	+$409K	﹤0.01%	1552

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Amalgamated Financial's KRTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2022: 3,634 shares worth $461K. The stake represents ﹤0.01% of the portfolio and ranks #1552 among its holdings.

177 funds tracked by Wall St. Rank hold KRTX as of Q1 2022.

Amalgamated Financial held 3,634 shares of Karuna Therapeutics, Inc. Common Stock worth $461K as of Q1 2022.
Karuna Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Karuna Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1552 holding.
177 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.